BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 19417213)

  • 1. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma.
    Fulciniti M; Tassone P; Hideshima T; Vallet S; Nanjappa P; Ettenberg SA; Shen Z; Patel N; Tai YT; Chauhan D; Mitsiades C; Prabhala R; Raje N; Anderson KC; Stover DR; Munshi NC
    Blood; 2009 Jul; 114(2):371-9. PubMed ID: 19417213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo.
    Yaccoby S; Ling W; Zhan F; Walker R; Barlogie B; Shaughnessy JD
    Blood; 2007 Mar; 109(5):2106-11. PubMed ID: 17068150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
    Heath DJ; Chantry AD; Buckle CH; Coulton L; Shaughnessy JD; Evans HR; Snowden JA; Stover DR; Vanderkerken K; Croucher PI
    J Bone Miner Res; 2009 Mar; 24(3):425-36. PubMed ID: 19016584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events.
    Iyer SP; Beck JT; Stewart AK; Shah J; Kelly KR; Isaacs R; Bilic S; Sen S; Munshi NC
    Br J Haematol; 2014 Nov; 167(3):366-75. PubMed ID: 25139740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlations of DKK1 with pathogenesis and prognosis of human multiple myeloma.
    Feng Y; Zhang Y; Wei X; Zhang Q
    Cancer Biomark; 2019; 24(2):195-201. PubMed ID: 30614800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma.
    Pozzi S; Fulciniti M; Yan H; Vallet S; Eda H; Patel K; Santo L; Cirstea D; Hideshima T; Schirtzinge L; Kuhstoss S; Anderson KC; Munshi N; Scadden D; Kronenberg HM; Raje N
    Bone; 2013 Apr; 53(2):487-96. PubMed ID: 23333523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma.
    Qiang YW; Barlogie B; Rudikoff S; Shaughnessy JD
    Bone; 2008 Apr; 42(4):669-80. PubMed ID: 18294945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma.
    Qian J; Zheng Y; Zheng C; Wang L; Qin H; Hong S; Li H; Lu Y; He J; Yang J; Neelapu S; Kwak LW; Hou J; Yi Q
    Blood; 2012 Jan; 119(1):161-9. PubMed ID: 22049519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclized Oligopeptide Targeting LRP5/6-DKK1 Interaction Reduces the Growth of Tumor Burden in a Multiple Myeloma Mouse Model.
    Park BM; Kim EJ; Nam HJ; Zhang D; Bae CH; Kang M; Kim H; Lee W; Bogen B; Lim SK
    Yonsei Med J; 2017 May; 58(3):505-513. PubMed ID: 28332354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1.
    Fowler JA; Mundy GR; Lwin ST; Edwards CM
    Cancer Res; 2012 May; 72(9):2183-9. PubMed ID: 22374979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancing motor functional recovery in spinal cord injury through pharmacological inhibition of Dickkopf-1 with BHQ880 antibody.
    González-Fernández C; González P; Maqueda A; Pérez V; Rodríguez FJ
    Biomed Pharmacother; 2024 Jul; 176():116792. PubMed ID: 38795645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
    Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
    Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-Targeting DKK1 and LRP6 Prevents Bone Loss and Improves Fracture Resistance in Multiple Myeloma.
    Simic MK; Mohanty ST; Xiao Y; Cheng TL; Taylor VE; Charlat O; Croucher PI; McDonald MM
    J Bone Miner Res; 2023 Jun; 38(6):814-828. PubMed ID: 36987921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.
    Tian E; Zhan F; Walker R; Rasmussen E; Ma Y; Barlogie B; Shaughnessy JD
    N Engl J Med; 2003 Dec; 349(26):2483-94. PubMed ID: 14695408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention.
    Zhou F; Meng S; Song H; Claret FX
    Blood Rev; 2013 Nov; 27(6):261-7. PubMed ID: 24054128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma.
    Fulciniti M; Hideshima T; Vermot-Desroches C; Pozzi S; Nanjappa P; Shen Z; Patel N; Smith ES; Wang W; Prabhala R; Tai YT; Tassone P; Anderson KC; Munshi NC
    Clin Cancer Res; 2009 Dec; 15(23):7144-52. PubMed ID: 19934301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia-induced CREB cooperates MMSET to modify chromatin and promote DKK1 expression in multiple myeloma.
    Xu Y; Guo J; Liu J; Xie Y; Li X; Jiang H; Wang J; Peng Z; Wang J; Wang S; Wan C; Chen L; Zhong Y; Liu B; Liu Z
    Oncogene; 2021 Feb; 40(7):1231-1241. PubMed ID: 33420361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation.
    Clines GA; Mohammad KS; Bao Y; Stephens OW; Suva LJ; Shaughnessy JD; Fox JW; Chirgwin JM; Guise TA
    Mol Endocrinol; 2007 Feb; 21(2):486-98. PubMed ID: 17068196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chrysosplenetin promotes osteoblastogenesis of bone marrow stromal cells via Wnt/β-catenin pathway and enhances osteogenesis in estrogen deficiency-induced bone loss.
    Hong G; He X; Shen Y; Chen X; Yang F; Yang P; Pang F; Han X; He W; Wei Q
    Stem Cell Res Ther; 2019 Aug; 10(1):277. PubMed ID: 31464653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo.
    Glantschnig H; Hampton RA; Lu P; Zhao JZ; Vitelli S; Huang L; Haytko P; Cusick T; Ireland C; Jarantow SW; Ernst R; Wei N; Nantermet P; Scott KR; Fisher JE; Talamo F; Orsatti L; Reszka AA; Sandhu P; Kimmel D; Flores O; Strohl W; An Z; Wang F
    J Biol Chem; 2010 Dec; 285(51):40135-47. PubMed ID: 20929859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.